close
MENU
Hot Topic Rich List
Hot Topic Rich List
The NBR List
5 mins to read

Featured NBR Listers: Douglas family

The family hopes 2021 will see completion of a clinical trial set to revolutionise treatment of severe depression.  

Tue, 25 May 2021

Category: Make & Sell

Approx. $420 million

See all profiles, rankings and feature articles on The NBR List 2021 home page.


Douglas Pharmaceuticals managing director Jeff Douglas’s high point of 2021 will be the completion of a clinical trial that is set to revolutionise the treatment

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual
Group membership
NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Featured NBR Listers: Douglas family
The NBR List,
87408
true